Overview
Most common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Mostly mild-moderate, titration-dependent. Management strategies.
Related guides
- 503A vs 503B Compounding Pharmacies Explained
- Semaglutide Cost Guide — Brand vs Compounded Pricing
- Semaglutide Dosing Schedule
- BMI Eligibility for Semaglutide Weight Management
- Compounded vs Brand-Name Semaglutide
- Semaglutide Insurance Coverage
- How Semaglutide Works — Mechanism Explained
- Semaglutide and Cardiovascular Health
Key facts, checked November 20, 2026
The Wegovy label lists a boxed warning about thyroid C-cell tumors in rodents and warnings for pancreatitis, gallbladder disease, low blood sugar, kidney injury, allergic reactions, diabetic eye complications, faster heart rate and suicidal thoughts. The Wegovy label lists nausea, diarrhea, vomiting, constipation and abdominal pain among its most common adverse reactions (5% or more of patients); the label raises the dose in steps every four weeks. On November 9, 2026, FDA’s November 9, 2026 safety communication required every approved GLP-1 label to add a possible increased risk of NAION, a sudden, painless loss of vision in one eye: 6.4 versus 3.8 cases per 100,000 person-years in FDA’s trial analysis. Call a clinician the same day for sudden vision loss.